Type 2 Diabetes


Eversense CGM

Evaluate the effectiveness of diabetes management with Eversense CGM system non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or type 2 diabetes.


Oral Insulin

In this randomized, double-blind, double-dummy, placebo-controlled study, approximately 675 eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3 oral glucose-lowering agents will undergo an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period and a 26-week Double-Blind Treatment Extension Period.



This trial compares the efficacy and safety of tirzepatide once weekly at either 5 mg, 10 mg, 15 mg dose to 3 times a day Lispro in patients with type 2 diabetes on glargine.

Can’t find a study that works for you?

Subscribe for Information on Other Studies

Fill out the form below an we will let you know when a study becomes available that you may be interested in:

Interested in other Studies
What other studies are you interested in?